Fibrosis progression according to epithelial-mesenchymal transition profile: A randomized trial of everolimus versus CsA

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1303-1312

  Rostaing, L ^a   Hertig, A ^b   Albano, L ^c   Anglicheau, D ^d   Durrbach, A ^e   Vuiblet, V ^f   Moulin, B ^g   Merville, P ^h   Hazzan, M ⁱ   Lang, P ^j   Touchard, G ^k   Hurault Deligny, B ^l   Quere S ^m   Di Giambattista, F ^m   Dubois, Y C ⁿ   Rondeau, E ^b,o  

^a CHU RANGUEIL   (France)

^b HÔPITAL TENON   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f HÔPITAL MAISON BLANCHE   (France)

^g HÔPITAL CIVIL   (France)

^h HÔPITAL PELLEGRIN   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k Hoà Pital la Mile Trie ^*  (France)

^l CAEN UNIVERSITY HOSPITAL   (France)

^m NOVARTIS PHARMA K K   (Japan)

ⁿ INSERM   (France)

^o SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

calcineurin inhibitor:cyclosporine A (CsA); fibrosis; immunosuppressant

Indexed keywords

BETA CATENIN; CREATININE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; STEROID; VIMENTIN; CALCINEURIN INHIBITOR;

ACNE; ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; APHTHOUS STOMATITIS; ARTICLE; BK VIRUS INFECTION; CONTROLLED STUDY; CREATININE URINE LEVEL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GINGIVA HYPERTROPHY; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; AGED; BIOPSY; DRUG EFFECTS; FIBROSIS; INFLAMMATION; KIDNEY; PATHOLOGY; PROSPECTIVE STUDY; RENAL INSUFFICIENCY; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BIOPSY; CALCINEURIN INHIBITORS; CYCLOSPORINE; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; EVEROLIMUS; FEMALE; FIBROSIS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84928023423     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13132     Document Type: Article

References (28)

1. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
2. Servais A, Meas-Yedid V, Toupance O, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552-2560.
3. Mota A, Arias M, Taskinen EI, et al. Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961.
4. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635-2646.
5. Hertig A, Verine J, Mougenot B, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006; 6: 2937-2946.
6. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584-1591.
7. Hazzan M, Hertig A, Buob D, et al. Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients. J Am Soc Nephrol 2011; 22: 1375-1381.
8. Xu-Dubois YC, Galichon P, Brocheriou I, et al. Expression of the transcriptional regulator snail1 in kidney transplants displaying epithelial-to-mesenchymal transition features. Nephrol Dial Transplant 2013; Sep 15. [Epub ahead of print].
9. Xu-Dubois YC, Baugey E, Peltier J, et al. Epithelial phenotypic changes are associated with a tubular active fibrogenic process in human renal grafts. Hum Pathol 2013; 44: 1251-1261.
10. Kers J, Xu-Dubois YC, Rondeau E, et al. Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy. Transplantation 2010; 90: 502-509.
11. Galichon P, Vittoz N, Xu-Dubois YC, et al. Epithelial phenotypic changes detect cyclosporine in vivo nephrotoxicity at a reversible stage. Transplantation 2011; 92: 993-998.
12. Kriz W, Kaissling B, Le Hir MJ,. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: Fact or fantasy. Clin Invest 2011; 121: 468-474.
13. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
14. Li L, Zepeda-Orozco D, Black R, Lin F,. Autophagy is a component of epithelial cell fate in obstructive uropathy. Am J Pathol 2010; 176: 1767-1778.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-470.
16. Budde K, Becker T, Arns W, et al. ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
17. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
18. Lee SB, Kalluri R,. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 2010; 119: S22-S26.
19. Nashan B,. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors. Transplant Rev 2009; 23: 47-52.
20. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509-2516.
21. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115-1123.
22. Mjörnstedt L, Sørensen SS, von Zur Mühlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744-2753.
23. Silva HT Jr, Felipe CR, Garcia VD, et al. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant 2013; 13: 3155-3163.
24. Guba M, Pratschke J, Hugo C, et al. SMART-Study Group. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 9: 175-183.
25. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011; 11: 1665-1675.
26. Thierry A, Thervet E, Vuiblet V, et al. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am J Transplant 2011; 11: 2153-2161.
27. Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant 2013; 27: 217-226.
28. Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM,. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010; 90: 31-37.